Subtenon Triamcinolone Acetonide Injection with Topical Anesthesia in Pediatric Non-Infectious Uveitis.
Macular edema
Ocular hypertension
Pediatric non-infectious uveitis
Pediatric uveitis
Periocular corticosteroid injection
Subtenon triamcinolone acetate injection
Topical anesthesia
Uveitic cataract
Journal
Ophthalmology and therapy
ISSN: 2193-8245
Titre abrégé: Ophthalmol Ther
Pays: England
ID NLM: 101634502
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
31
12
2021
accepted:
03
02
2022
pubmed:
19
2
2022
medline:
19
2
2022
entrez:
18
2
2022
Statut:
ppublish
Résumé
Subtenon triamcinolone acetonide (Kenalog®; Bristol Myers Squibb) (STA) injections are commonly used in the treatment of adults in an outpatient setting. However, publications on detailing its outpatient use, safety, and efficacy in the pediatric population are scarce. We reviewed STA injections performed in children in the outpatient clinics at two tertiary centers from 2014 to 2020. All children were aged ≤ 18 years and had a diagnosis of non-infectious uveitis. STA injections were done using 0.5 cc (20 mg) triamcinolone injected superotemporally with only topical anesthesia. Data on the efficacy and safety of STA in treating inflammation and compiled data on visual acuity improvement and incidence of ocular complications were evaluated. Forty-eight eyes in 30 patients were included. The mean age of patients was 13.1 (range 7-18) years. There were no immediate complications observed in all injections performed. At the 3-month follow-up, inflammation had improved in 85.4% of eyes, macular edema had resolved in 77.8% of eyes, and there was significant vision improvement after STA. At 6 months after STA, the incidence of ocular hypertension was 12.5% and no new cataracts had developed. STA injection with topical anesthesia was a well-tolerated, reasonable alternative for short-term treatment of uveitis among this pediatric population.
Identifiants
pubmed: 35179713
doi: 10.1007/s40123-022-00480-4
pii: 10.1007/s40123-022-00480-4
pmc: PMC8927513
doi:
Types de publication
Journal Article
Langues
eng
Pagination
811-820Informations de copyright
© 2022. The Author(s).
Références
Smith JA, Mackensen F, Sen HN, et al. Epidemiology and course of disease in childhood uveitis. Ophthalmology. 2009;116(8):1544–51.
doi: 10.1016/j.ophtha.2009.05.002
Rosenberg KD, Feuer WJ, Davis JL. Ocular complications of pediatric uveitis. Ophthalmology. 2004;111(12):2299–306.
doi: 10.1016/j.ophtha.2004.06.014
Kump LI, Cervantes-Castaneda RA, Androudi SN, Foster CS. Analysis of pediatric uveitis cases at a tertiary referral center. Ophthalmology. 2005;112(7):1287–92.
doi: 10.1016/j.ophtha.2005.01.044
McKay KM, Borkar DS, Sevgi DD, Susarla G, Papaliodis GN, Sobrin L. Comparison of modified posterior sub-tenon’s vs. trans-septal triamcinolone injection for non-infectious uveitis. Ocul Immunol Inflamm. 2020;2:1–8.
Thomas AS, Lin P. Local treatment of infectious and noninfectious intermediate, posterior, and panuveitis: current concepts and emerging therapeutics. Curr Opin Ophthalmol. 2020;31(3):174–84.
doi: 10.1097/ICU.0000000000000651
Salek SS, Leder HA, Butler NJ, Gan TJ, Dunn JP, Thorne JE. Periocular triamcinolone acetonide injections for control of intraocular inflammation associated with uveitis. Ocul Immunol Inflamm. 2013;21(4):257–63.
doi: 10.3109/09273948.2013.767353
Sen HN, Vitale S, Gangaputra SS, et al. Periocular corticosteroid injections in uveitis: effects and complications. Ophthalmology. 2014;121(11):2275–86.
doi: 10.1016/j.ophtha.2014.05.021
Thorne JE, Sugar EA, Holbrook JT, et al. Periocular triamcinolone vs intravitreal triamcinolone vs intravitreal dexamethasone implant for the treatment of uveitic macular edema: The PeriOcular vs INTravitreal corticosteroids for uveitic macular edema (POINT) trial. Ophthalmology. 2019;126(2):283–95.
doi: 10.1016/j.ophtha.2018.08.021
Giles CL. Peripheral uveitis in children. J Pediatr Ophthalmol. 1977;14(2):93–5.
pubmed: 874714
Habot-Wilner Z, Sallam A, Roufas A, et al. Periocular corticosteroid injection in the management of uveitis in children. Acta Ophthalmol. 2010;88(8):e299-304.
doi: 10.1111/j.1755-3768.2010.02025.x
Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature Working G. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509–16.
doi: 10.1016/j.ajo.2005.03.057
Yanni SE, Wang J, Cheng CS, et al. Normative reference ranges for the retinal nerve fiber layer, macula, and retinal layer thicknesses in children. Am J Ophthalmol. 2013;155(2):354–60.
doi: 10.1016/j.ajo.2012.08.010
Ferreira BG, Marinho DR, Diligenti FT. Effects of sub-Tenon’s triamcinolone injections in patients with uveitis. Arq Bras Oftalmol. 2018;81(4):323–9.
doi: 10.5935/0004-2749.20180063
Angeles-Han ST, Lo MS, Henderson LA, et al. Childhood arthritis and rheumatology research alliance consensus treatment plans for juvenile idiopathic arthritis-associated and idiopathic chronic anterior uveitis. Arthritis Care Res (Hoboken). 2019;71(4):482–91.
doi: 10.1002/acr.23610
Gautam Seth N, Kaur S, Yangzes S, et al. Ophthalmic complications in pediatric uveitis. Ocul Immunol Inflamm. 2020;2:1–6.
Sancho L, Kramer M, Koriat A, Eiger-Moscovich M, Sharon Y, Amer R. Complications in intermediate uveitis: prevalence, time of onset, and effects on vision in short-term and long-term follow-up. Ocul Immunol Inflamm. 2019;27(3):447–55.
doi: 10.1080/09273948.2017.1420203
Gautam Seth N, Yangzes S, Thattaruthody F, et al. Glaucoma secondary to uveitis in children in a tertiary care referral center. Ocul Immunol Inflamm. 2019;27(3):456–64.
doi: 10.1080/09273948.2017.1411517
Eiger-Moscovich M, Tomkins-Netzer O, Amer R, et al. Visual and clinical outcome of macular edema complicating pediatric noninfectious uveitis. Am J Ophthalmol. 2019;202:72–8.
doi: 10.1016/j.ajo.2019.02.011
Kothari S, Foster CS, Pistilli M, et al. The risk of intraocular pressure elevation in pediatric noninfectious uveitis. Ophthalmology. 2015;122(10):1987–2001.
doi: 10.1016/j.ophtha.2015.06.041